Covington & Burling advised AbbVie on the transaction, and Fenwick & West advised Aliada Therapeutics. AbbVie (NYSE: ABBV), a pharmaceutical firm, announced it has entered into...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Rupa Health in the transaction. Rupa Health, a company that helps practitioners order, track and manage more than 3,000 laboratory tests in...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented NextRNA Therapeutics in the transaction. NextRNA Therapeutics (NextRNA), a biotechnology company, announced a collaboration and licensing agreement with Bayer to develop small...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Morphic Holdings, Inc. in the transaction, and Kirkland & Ellis represented Eli Lilly and Company. Eli Lilly and Company (NYSE: LLY) announced...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Formation Bio in the transaction, and Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Thrive Capital. Formation Bio, a NYC-based tech-driven and...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Day One Biopharmaceuticals in the transaction. Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One”), a commercial-stage biopharmaceutical company announced its exclusive licensing agreement...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Belharra Therapeutics in the transaction. Belharra Therapeutics (Belharra) announced it has entered into a collaboration with Sanofi to advance the discovery of...
You must be a Standard 1 Year member to access this content.
Fenwick & West is advising Escient Pharmaceuticals on the transaction, and Covington & Burling is advising Incyte. Incyte (Nasdaq:INCY) announced the acquisition of Escient Pharmaceuticals (“Escient”). Incyte...
You must be a Standard 1 Year member to access this content.
Freshfields Bruckhaus Deringer is representing Johnson & Johnson in the transaction, and Fenwick & West is representing Shockwave Medical. Johnson & Johnson (NYSE: JNJ) and Shockwave Medical,...
You must be a Standard 1 Year member to access this content.
Skadden advised Vertex Pharmaceuticals Incorporated, while Fenwick & West advised Alpine in the transaction. Vertex Pharmaceuticals Incorporated and Alpine Immune Sciences, Inc. have entered into a definitive...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Synthego in the transaction. EditCo Bio, Inc. announced that it has launched its business with the acquisition of Synthego’s engineered cell solutions...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Atara Biotherapeutics, Inc. in the transaction. Atara Biotherapeutics, Inc. (Nasdaq: ATRA) announced it has entered into an expanded partnership with Pierre Fabre...
You must be a Standard 1 Year member to access this content.
